secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2024-02-21T23:59:59+00:00
Accession:  0001367644-24-000006
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions appoints Joseph C. Papa as President and CEO, replacing interim CEO Haywood Miller
--------------------------------------------------------------------------------

- Joseph C. Papa appointed President and CEO effective Feb 21, 2024; succeeds interim CEO Haywood Miller.
- Papa brings over 35 years pharma experience, most recently CEO of Bausch + Lomb (NYSE: BLCO).
- Compensation: $1M base salary, 130% bonus target, $1M sign-on bonus, 1.5M stock options, $8M performance incentive tied to share price.
- Also appointed Class II director with term through 2026 annual meeting.
- Press release emphasizes focus on strengthening balance sheet, returning to growth, and paying down debt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000006/0001367644-24-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000006/ebs-20240220.htm
  HTML page:      https://secwatch.observer/filing/0001367644-24-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer